Fig. 1: Schematic showing Δ9-THC and 11-OH-THC PBPK model development and verification for inhalation and oral consumption of Δ9-THC by the non-pregnant population followed by extension to the pregnant population (m-f-PBPK model). | Nature Communications

Fig. 1: Schematic showing Δ9-THC and 11-OH-THC PBPK model development and verification for inhalation and oral consumption of Δ9-THC by the non-pregnant population followed by extension to the pregnant population (m-f-PBPK model).

From: Quantification and prediction of human fetal (-)-Δ9-tetrahydrocannabinol/(±)-11-OH-Δ9-tetrahydrocannabinol exposure during pregnancy to inform fetal cannabis toxicity

Fig. 1

First, the model was built in Simcyp V22 for the healthy non-pregnant population by optimizing and verifying the Δ9-THC elimination and distribution kinetics after intravenous administration. Then, Δ9-THC absorption kinetics and 11-OH-THC elimination and distribution kinetics were verified after inhalation and oral Δ9-THC consumption. The Δ9-THC kinetics in the non-pregnant model were also verified through drug-drug interaction and pharmacogenetic studies. Then, using our in-house m-f-PBPK model, built in MATLAB Simulink R2023a, which includes the placental and fetal compartments as well as gestational age-dependent physiological changes, the umbilical venous plasma (UVP) and fetal tissue concentrations were predicted. Figure was created with BioRender.com.

Back to article page